Could an antidepressant help curb meth use in people treated for opioid addiction?

NCT ID NCT06323837

Recruiting now Disease control Sponsor: Washington State University Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This phase 2 trial tests whether mirtazapine, an antidepressant, can help adults who are already receiving medication for opioid use disorder to stop or reduce their methamphetamine use. Participants are randomly assigned to receive either mirtazapine or a placebo for 10 weeks, alongside their usual treatment. The study measures methamphetamine abstinence through urine tests and also tracks sleep improvements.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mirtazapine
What this could lead to: If it works, mirtazapine could become a new treatment option to help people reduce or stop methamphetamine use while receiving medication for opioid use disorder.
What could go wrong: This is a small, early-phase trial with only 60 participants. The drug may not prove more effective than placebo, and results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METHAMPHETAMINE USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

methamphetamine dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STIMULANT USE DISORDER

Contacts and locations

Locations

Spokane Treatment Center
RECRUITING

Spokane, Washington, 99208, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.